Drugs / CIK cells
last change Mar 2026 re-read 9 days ago

CIK cells

Cell therapy

Developed for
hepatocellular carcinoma · myelodysplastic syndrome · renal cell carcinoma · acute leukemia · chronic myeloid leukemia · non-small cell lung carcinoma · plasma cell myeloma · small cell lung carcinoma
+18 more · acute lymphoblastic leukemia · acute myeloid leukemia · B-cell neoplasm · cancer · clear cell renal carcinoma · colorectal carcinoma · disease related to hematopoietic stem cell transplant · esophageal cancer · Hodgkins lymphoma · kidney cancer · leukemia · lung cancer · nasopharyngeal carcinoma · neoplasm · pancreatic ductal adenocarcinoma · pleural neoplasm · colorectal cancer · myeloproliferative neoplasm
Investigated by
Affiliated Hospital to Academy of Military Medical Sciences · People's Hospital of Guangxi Zhuang Autonomous Region · Singapore General Hospital · Sun Yat-sen University · Tianjin Medical University Cancer Institute and Hospital · Affiliated Hospital of Jiangnan University
+25 more · Alliancells-PuRui Biocience Co., Ltd. · Allife Medical Science and Technology Co., Ltd. · Beijing Hospital · Chinese PLA General Hospital · Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran · Everett Meyer · Fuzhou General Hospital · Han weidong · Henan Provincial People's Hospital · Hunan Cancer Hospital · LucasBio · Ministry of Health and Medical Education · National Medical Research Council (NMRC), Singapore · Peter Bader · Sabz Biomedicals · Sally Arai · Shenzhen Second People's Hospital · Sichuan University · The First People's Hospital of Changzhou · The First People's Hospital of Yunnan · University of Malaya · West China Hospital · Wuxi People's Hospital · Zhejiang Provincial People's Hospital · Zhongyuan Union Stem Cell Bio-engineering Corporation

Trials 25

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03815630 Feb 2019 → Feb 2020 neoplasm Allife Medical Science and Technology Co., Ltd. Unknown No outcome recorded
Phase 13 trials
Phase 1 NCT05268172 Dec 2022 → Dec 2024 pleural neoplasm Affiliated Hospital of Jiangnan University Unknown No outcome recorded
Phase 1 NCT01914263 Mar 2014 → Apr 2016 hepatocellular carcinoma, lung cancer, renal cell carcinoma Alliancells-PuRui Biocience Co., Ltd. Unknown No outcome recorded
Phase 1 NCT00477035 May 2006 → Mar 2011 leukemia, plasma cell myeloma Sally Arai Completed No outcome recorded
Phase 1/29 trials · 1 met primary
Phase 1/2 NCT03329664 Feb 2020 → Sep 2021 colorectal carcinoma Sabz Biomedicals Unknown No outcome recorded
Phase 1/2 NCT02752243 Mar 2016 → Mar 2023 acute leukemia, myelodysplastic syndrome Peter Bader Unknown No outcome recorded
Phase 1/2 NCT02693236 Aug 2014 → Aug 2016 esophageal cancer Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT02688673 Aug 2014 → Aug 2016 small cell lung carcinoma Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT01956630 Sep 2013 → Sep 2016 acute leukemia Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT01924156 Jul 2013 → Dec 2016 renal cell carcinoma Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT01799083 Dec 2012 → Dec 2016 B-cell neoplasm, cancer Han weidong Unknown Met primary
Phase 1/2 NCT00862303 Mar 2009 → Jun 2015 renal cell carcinoma Fuzhou General Hospital Unknown No outcome recorded
Phase 1/2 NCT00460694 Aug 2006 → Dec 2012 Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +2 Singapore General Hospital Completed No outcome recorded
Phase 27 trials · 1 missed
Phase 2 NCT04836728 Mar 2021 → Apr 2024 overdue non-small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital Active not recruiting No outcome recorded
Phase 2 NCT03987698 Jun 2019 → Jun 2022 clear cell renal carcinoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 2 NCT02487550 Aug 2015 → Jul 2028 expected kidney cancer The First People's Hospital of Changzhou Not yet recruiting No outcome recorded
Phase 2 NCT01592422 Jul 2012 → Jul 2015 small cell lung carcinoma People's Hospital of Guangxi Zhuang Autonomous Region Unknown No outcome recorded
Phase 2 NCT01655628 Jul 2012 → Jul 2014 nasopharyngeal carcinoma Sun Yat-sen University Unknown No outcome recorded
Phase 2 NCT01392989 Mar 2011 → Jun 2016 anemia, myelodysplastic syndrome, myeloid leukemia, neural tube defect Everett Meyer Completed Missed primary
Phase 2 NCT00815321 Dec 2008 → Nov 2011 chronic myeloid leukemia Singapore General Hospital Completed No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT05955157 Jan 2023 → Dec 2024 pancreatic ductal adenocarcinoma University of Malaya Unknown No outcome recorded
Phase 2/3 NCT01481259 Jan 2010 → Jan 2013 non-small cell lung carcinoma People's Hospital of Guangxi Zhuang Autonomous Region Unknown No outcome recorded
Phase 2/3 NCT02851784 Dec 2009 → Dec 2028 expected hepatocellular carcinoma Chinese PLA General Hospital Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT00769106 Jun 2008 → Sep 2014 hepatocellular carcinoma Sun Yat-sen University Completed No outcome recorded
Phase not applicable1 trial
— NCT07692607 Mar 2022 → Feb 2025 disease related to hematopoietic stem cell transplant LucasBio Completed No outcome recorded
Comparator or background therapy2 trials
Phase 1 NCT03282435 Comparator Jan 2018 → Jan 2023 non-small cell lung carcinoma Dalian University Unknown No outcome recorded
Phase 2 NCT03524274 Comparator Apr 2018 → May 2020 colorectal cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded Stop: Enrollment

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 28 sources stand behind the page.

FieldValueCited text
Known as CIK cells “Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities...” PMID 24720900 ↗ Apr 2014
19

“Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.” NCT02487550 ↗

“ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy” NCT00815321 ↗

“CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1” NCT03524274 ↗

“CIK cells were infused intravenously.” NCT02851784 ↗

“infusion of CIK cells” NCT00862303 ↗

NCT03282435 ↗

NCT05268172 ↗

NCT01655628 ↗

NCT01956630 ↗

NCT04836728 ↗

Show 9 more sources

Known as Autologous cytokine-induced killer cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT01592422 ↗
1

NCT01481259 ↗

Known as CIK “cytokine-induced killer cell (CIK) treatment” NCT00769106 ↗
1

“Cytokine-Induced Killer Cell (CIK)” NCT02487550 ↗

Known as cytokine induced killer cells “CIK cells (cytokine induced killer cells, CIK) are a population of heterogeneous cells generated by the in vitro amplification of mononuclear cells in peripheral blood.” NCT01655628 ↗
Known as Cytokine-induced killer “Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities...” PMID 24720900 ↗ Apr 2014
Known as Cytokine-induced killer (CIK) cells “Thus, we aimed to find an innovative strategy to refine therapeutic applications and improve their outcomes by examining the potential of cytokine-induced killer (CIK) cells.” PMID 41520915 ↗ Jan 2026
1

“ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy” NCT00815321 ↗

Known as Cytokine-Induced Killer Cell “Cytokine-Induced Killer Cell (CIK)” NCT02487550 ↗
5

NCT05955157 ↗

NCT03329664 ↗

NCT00769106 ↗

NCT01799083 ↗

NCT01914263 ↗

Action Deplete “Cytokine-induced killer ( CIK ) cells have been shown by our lab to be cytolytic against both autologous and allogeneic acute myeloid leukemia ( AML ) cells.” NCT00460694 ↗
Modality Cell therapy “immunotherapy with allogeneic CIK cells” NCT00460694 ↗
Route Other “then infused into patients” NCT00460694 ↗